Genomic Testing in the NCI-MATCH Cancer Trial

To find patients who may be eligible, several commercial and academic laboratories were permitted by the National Cancer Institute to identify and refer potentially eligible patients to the trial. These referrals were based upon each labโ€™s standard tumor gene tests ordered by physicians at participating trial sites to guide clinical care for their patients.

The laboratory referral process applied to any cancer patient who had tumor gene testing through a cancer center or community hospital that participated in the trial.ย NCI-MATCH was open at nearly 1100 clinical sites in every state, the District of Columbia, and Puerto Rico.

The trial closed to patient enrollment on December 23, 2022.

Designated Commercial Laboratories

Ashion Analytics
Caris Life Sciences
CellNetix Pathology and Laboratories
Foundation Medicine
GenPath (BioReference Laboratories)
NeoGenomics Laboratories
Quest Diagnostics
Strata Oncology
Tempus Labs
The Jackson Laboratory

Designated Academic Laboratories

Augusta University
Brigham and Womenโ€™s Hospital
Cedars-Sinai Medical Center
City of Hope National Medical Center
Columbia University
Frederick National Laboratory for Cancer Research
Johns Hopkins Genomics
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
National Cancer Institute โ€“ Laboratory of Pathology
Stanford Health Care
The University of Texas MD Anderson Cancer Center
University of Chicago
University of Colorado
University of Michigan
University of Washington
Weill Cornell Medicine
Yale University

ECOG-ACRIN Cancer Research Group